Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1994 2
1996 1
2000 1
2002 3
2005 5
2006 1
2007 5
2008 8
2009 5
2010 6
2011 2
2012 5
2013 9
2014 6
2015 3
2016 4
2017 6
2018 2
2019 1
2020 6
2021 4
2022 6
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma.
Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, Gao C, Lu H, Wang X, Cao P, Chen H, Lu S, Zhou G. Lu Y, et al. Nat Commun. 2022 Aug 6;13(1):4594. doi: 10.1038/s41467-022-32283-3. Nat Commun. 2022. PMID: 35933472 Free PMC article.
Finally, we identify seven microenvironment-based subtypes that can predict prognosis of HCC patients. Collectively, this large-scale atlas deepens our understanding of the HCC microenvironment, which might facilitate the development of new immune therapy strategies for th …
Finally, we identify seven microenvironment-based subtypes that can predict prognosis of HCC patients. Collectively, this large-scale …
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma.
Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song M, Ji Y, Zang F, Lou L, Rao K, Wang P, Gu Y, Gu J, Lu B, Chen L, Pan X, Zhao X, Peng L, Liu D, Chen X, Wu K, Lin P, Wu L, Su Y, Du M, Hou Y, Yang X, Qiu S, Shi Y, Sun H, Zhou J, Huang X, Peng DH, Zhang L, Fan J. Sun Y, et al. Cancer Cell. 2024 Jan 8;42(1):135-156.e17. doi: 10.1016/j.ccell.2023.11.010. Epub 2023 Dec 14. Cancer Cell. 2024. PMID: 38101410
Comprehensive molecular analyses of metastatic hepatocellular carcinoma (HCC) are lacking. Here, we generate multi-omic profiling of 257 primary and 176 metastatic regions from 182 HCC patients. ...Genomic divergence between primary and metastatic HCC is high …
Comprehensive molecular analyses of metastatic hepatocellular carcinoma (HCC) are lacking. Here, we generate multi-omic …
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F. Qin S, et al. J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29. J Clin Oncol. 2021. PMID: 34185551 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score 7, and no prior systemic therapy from 37 sites across China. ...
PATIENTS AND METHODS: This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable o …
A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.
Goodwin CR, Yanamadala V, Ruiz-Valls A, Abu-Bonsrah N, Shankar G, Sankey EW, Boone C, Clarke MJ, Bilsky M, Laufer I, Fisher C, Shin JH, Sciubba DM. Goodwin CR, et al. World Neurosurg. 2016 Jul;91:510-517.e4. doi: 10.1016/j.wneu.2016.04.026. Epub 2016 May 13. World Neurosurg. 2016. PMID: 27090971 Free PMC article. Review.
RESULTS: There were 26 articles (152 patients) that met the inclusion criteria and were treated with either surgery, radiotherapy, chemotherapy, and/or observation. There were 3 retrospective cohort studies, 17 case reports, 5 case series, and 1 longitudinal observation …
RESULTS: There were 26 articles (152 patients) that met the inclusion criteria and were treated with either surgery, radiotherapy, chemother …
Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma.
Kim S, Kim JH, Ko GY, Gwon DI, Shin JH, Yoon HK. Kim S, et al. Sci Rep. 2022 Apr 28;12(1):6906. doi: 10.1038/s41598-022-10972-9. Sci Rep. 2022. PMID: 35484185 Free PMC article.
BAE is an effective and safe option for the treatment of hemoptysis in patients with pulmonary metastasis from HCC, with a favorable clinical success rate and a low rate of hemoptysis recurrence. In addition, we also observed BAE to have a positive antitumor effect on pulm …
BAE is an effective and safe option for the treatment of hemoptysis in patients with pulmonary metastasis from HCC, with a favorable clinica …
Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis?
Kumar D, Hafez O, Jain D, Zhang X. Kumar D, et al. Hum Pathol. 2021 Jul;113:39-46. doi: 10.1016/j.humpath.2021.04.008. Epub 2021 Apr 24. Hum Pathol. 2021. PMID: 33905775
Studies comparing the histomorphologic features and phenotypic heterogeneity between primary and its corresponding metastatic hepatocellular carcinoma (HCC) are lacking. The aim of this study was to assess and compare the histomorphologic features and heterog …
Studies comparing the histomorphologic features and phenotypic heterogeneity between primary and its corresponding metastatic hepa …
Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective.
Abbas A, Medvedev S, Shores N, Bazzano L, Dehal A, Hutchings J, Balart L. Abbas A, et al. Dig Dis Sci. 2014 Nov;59(11):2813-20. doi: 10.1007/s10620-014-3229-9. Epub 2014 Jun 6. Dig Dis Sci. 2014. PMID: 24903653
Compared with Caucasian, African American ethnicity was an independent predictor of metastasis in both the NIS [OR 1.13 (1.02-1.25)] and UHC [OR 1.4 (1.3-1.6)] databases. ...Lungs were the most common metastatic site. Ethnicity and insurance status are independent predi …
Compared with Caucasian, African American ethnicity was an independent predictor of metastasis in both the NIS [OR 1.13 (1.02-1.25)] …
Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Govindarajan R, Siegel E, Makhoul I, Williamson S. Govindarajan R, et al. Am J Clin Oncol. 2013 Jun;36(3):254-7. doi: 10.1097/COC.0b013e318248d83f. Am J Clin Oncol. 2013. PMID: 22643560 Clinical Trial.
CONCLUSIONS: The 28% progression-free survival rate at 27 weeks was not significantly higher than the recent historical control rate of 20% observed on the placebo arm of the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol trial (P=0.28). ...
CONCLUSIONS: The 28% progression-free survival rate at 27 weeks was not significantly higher than the recent historical control rate of 20% …
A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study.
Abdel-Rahman O. Abdel-Rahman O. Int J Colorectal Dis. 2020 May;35(5):911-920. doi: 10.1007/s00384-020-03568-0. Epub 2020 Mar 17. Int J Colorectal Dis. 2020. PMID: 32185469 Review.

Using Kaplan-Meier survival comparison for the three temporal cohorts, the following survival observations were noted: for patients with metastatic esophageal adenocarcinoma: median survival for cohort-1: 8 months, cohort-2: 9 months, cohort-3: 9 months; P < 0.001; for

…
Using Kaplan-Meier survival comparison for the three temporal cohorts, the following survival observations were noted: for patients w …
Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles.
Wang FB, Rong Y, Fang M, Yuan JP, Peng CW, Liu SP, Li Y. Wang FB, et al. Biomaterials. 2013 May;34(15):3816-27. doi: 10.1016/j.biomaterials.2013.02.018. Epub 2013 Mar 7. Biomaterials. 2013. PMID: 23465488 Free article.
Metastatic recurrence is the most important biological behavior of hepatocellular carcinoma (HCC) and the main cause of treatment failure. Early prediction of metastasis is currently impossible due to the lack of specific molecular probes to recognize metastatic HCC cells. …
Metastatic recurrence is the most important biological behavior of hepatocellular carcinoma (HCC) and the main cause of treatment failure. E …
89 results